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Lupus Flare vs Macrophage Activation Syndrome
Amy McGhee, MD
InTroduCTIon
Macrophage activation syndrome (MAS), first named in 
1993, is a subcategory of hemophagocytic lymphohistio-
cytosis (HLH), characterized by prolonged fever, hepato-
splenomegaly, pancytopenia, liver dysfunction, and most 
notably hyperferritinemia. MAS, in particular, is the term 
used to describe secondary HLH, or HLH caused by 
rheumatologic conditions. Secondary HLH can also be 
associated with other systemic autoimmune diseases, 
underlying malignancy, infection, or medications and can 
be a life-threatening complication. MAS is characterized 
by unwarranted proliferation and stimulation of T cells 
and benign macrophages leading to an excessive 
inflammatory state with hypersecretion of cytokines. 
This, in turn, leads to phagocytosis of normal blood cells 
and injury to the organs containing these macrophages 
(liver, spleen, bone marrow, lymph nodes). With regard 
to rheumatologic conditions, MAS is most often seen 
associated with juvenile idiopathic arthritis (incidence of 
7-13%) while it is much less commonly seen in systemic 
lupus erythematosus (SLE) with an incidence of 0.9-4.6%. 
The etiology is unknown, although there are hypotheses.
CaSE PrESEnTaTIon
A 53 year old female with SLE complicated by lupus 
nephritis and lupus anticoagulant initially presented with 
a syncopal episode. While walking out of the rheuma-
tologist office, she felt faint and had an assisted fall to 
the floor with transient loss of consciousness. The patient 
reported approximately 1-2 months of decreased oral 
intake, weight loss, daily fevers to 102-103°F, lighthead-
edness, dry cough, and 1 week of rash on her upper 
chest. During this time, her rheumatologist adjusted her 
SLE medications, attributing her symptoms to a SLE flare. 
Work up during this admission (labs listed in Table 1) ruled 
out sepsis as a source of fever. It was determined that her 
symptoms and lab abnormalities were likely secondary to a 
lupus flare given her fever, rash, constitutional symptoms, 
and pancytopenia in the setting of SLE that was difficult 
to control. Early macrophage activation syndrome (MAS) 
was also on the differential given the elevated ferritin 
level. Her symptoms improved with pulse dose steroids 
and resuming mycophenolate mofetil for immunosup-
pression. The plan was to change this to cyclosporine as 
an outpatient to prevent MAS. 
Before switching to cyclosporine however, the patient 
was readmitted for recurrent fevers, fatigue, diarrhea, and 
worsening lab abnormalities. On admission, her physical 
exam was significant for fever to 102.4°F, tachycardia, 
and dry mucus membranes. Labs are shown in Table 
2. The most remarkable finding was a ferritin of 11,741 
which was a significant increase from 4,542 during her 
last admission. The patient underwent a bone marrow 
biopsy, which demonstrated increased macrophages with 
hemophagocytic activity, confirming a diagnosis of MAS. 
dIFFErEnTIal dIagnoSIS
In an SLE patient with recent flare 4 months ago, a 
recurrent lupus flare was highest on the differential as the 
patient reported joint pain, skin rash, fevers, weight loss, 
and fatigue. Infection is also high on the differential for 
a patient on chronic immunosuppression who presents 
with fever. An infectious workup was undertaken 
including a Right upper quadrant ultrasound, chest CT, 
blood cultures, urine cultures, respiratory viral panel, 
and transthoracic echo, all of which were negative for 
infection. Anti-dsDNA antibodies were unexpectedly 
normal and complement levels were unremarkable 
which made a SLE flare less likely. 
During the initial admission, the hyperferritinemia, an 
acute phase reactant, was thought to be elevated in 
the setting of a lupus flare or infection. However, the 
dramatic increase to 11,741 upon readmission raised 
suspicion for MAS. Multiple case reports have described 
this diagnostic difficulty in distinguishing between MAS 
and a SLE flare. It has been reported that elevation of 
ferritin (greater than or equal to 500ug/L) and LDH can 
help differentiate as this represents activation of the 
mononuclear phagocyte system. Hyperferritinemia has 
a sensitivity and specificity of almost 100% for distin-
guishing between a SLE flare and MAS. Lastly, a bone 
marrow biopsy is usually diagnostic for MAS if there is 
still uncertainty.
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Table 1. Labs for first admission.
Lab Result Lab Result
WBC (B/L) 1.2         L AST (U/L) 71       H
Hemoglobin (g/dL) 7.4         L ALT (U/L) 23
Platelets (B/L) 178 Alk phosphatase (U/L) 35
Sodium (mmol/L) 137 Lactate (mmol/L) 1.1
Potassium (mmol/L) 4.4 Iron (mcg/dL) 44
Chloride (mmol/L) 103
Iron Binding Capacity (mcg/
dL)
179      L
Bicarbonate (mmol/L) 22          L Iron Saturation (%) 25
BUN (mg/dL) 21 Ferritin (ng/mL) 4542    H
Creatinine (mg/dL) 0.9 ESR (mm/hr) 114      H
Glucose (mg/dL) 127 CRP (mg/dL) 1.50     H
PTT (sec) 42           H C3 complement (mg/dL) 79        L
PT (sec)  10.1 C4 complement (mg/dL) 12
INR 0.93 Anti-dsDNA Ab (IU) 25
Total Protein (g/dL) 5.1          L Haptoglobin (mg/dL) 295      H
Albumin (g/dL) 2.8          L LDH (IU/L) 396      H
Total bilirubin (mg/dL) 0.2 Vitamin B12 (pg/mL) 433
Direct bilirubin (mg/dL) <0.2 Folate (ng/mL) >20
Urinalysis 2+ protein
Trace blood
1 RBC 4 WBC
Table 2. Labs upon second admission.
Lab Result Lab Result
WBC (B/L) 0.9       L AST (U/L) 128      H
Hemoglobin (g/dL) 8.5       L ALT (U/L) 49        H
Platelets (B/L) 72        L Alk phosphatase (U/L) 41
Total Protein (g/dL) 5.6       L Ferritin (ng/mL) 11741  H
Albumin (g/dL) 3.1       L LDH (IU/L) 1135    H
Total bilirubin (mg/dL) 0.6
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ouTCoME and Follow-uP
Once the diagnosis of MAS was confirmed, the patient 
was treated with cyclosporine, anakinra (IL-1 receptor 
blocker), and high dose steroids. These were uptitrated 
until the ferritin, leukopenia, and liver function tests 
began to improve. Interestingly, in the work-up of the 
patient’s pancytopenia, her EBV studies showed a positive 
VCA IgG and ENA IgG so the patient was also treated 
with IVIG in case an EBV infection was contributing 
to the MAS. The patient was discharged home after a 
month-long hospitalization.  In the next nine months, 
her medications were all gradually tapered and she had 
a concordant improvement in ferritin, blood counts, and 
symptoms.
dISCuSSIon
There remain many uncertainties surrounding MAS 
including its etiology, treatment, and prognosis. In 
one case study of a patient with SLE and MAS, the 
patient tested positive for numerous antibodies (ANA, 
anti-dsDNA, anti-Sm, anti-RNP, anti-Ro, and peripheral 
ANCA antibodies). It was hypothesized that the 
overwhelming amount of autoantibodies and immune 
complexes bound to normal blood cells trigger 
phagocytosis of those cells. It is possible that the quantity 
of these autoantibodies and the increased complement 
activity during a SLE flare can trigger MAS.
Once the diagnosis of MAS is made, it is important to 
initiate therapy quickly as it can be a life-threatening 
illness. The cornerstone of therapy is high dose steroids. 
Multiple case reports also discuss the importance of 
immunosuppressant medications, such as cyclosporine 
A and cyclophosphamide in patients who do not respond 
to steroids, such as the patient in this report. One study, 
in particular, demonstrated 54% of patients with MAS 
from systemic autoimmune disease who received only 
high dose steroids were resistant to this treatment and 
the majority of patients who were treated with both 
steroids and immunosuppression had good treatment 
response. Another case report demonstrated the fairly 
rapid improvement in labs and clinical condition of a 
young man who was treated with cyclosporine when 
he did not respond to steroids. IVIG is another treatment 
option which is especially useful in patients who are 
suspected to have an underlying viral infection. Further, 
the next line of treatment if both steroids and immuno-
suppression are not effective is biologic agents, such 
as anakinra and rituximab. Anakinra is an IL-1 receptor 
blocker that has been used effectively in patients 
with MAS secondary to SLE which did not respond to 
steroids, IVIG, and cyclosporine. There is also evidence 
that rituximab is effective in treating resistant MAS. The 
patient in this case study did not respond appropriately 
to pulse dose steroids, cyclosporine, or IVIG, so she was 
started on anakinra and did well after a few weeks on 
this regimen. 
Further, prognosis is another area of uncertainty in MAS. 
There have been no prognostic indicators established 
yet but there is evidence suggesting the level of certain 
cytokines can be associated with a worse prognosis and 
that ferritin levels may help predict outcome. Multiple 
studies have found no correlation between ferritin 
levels and the severity of disease or outcome; however, 
serial ferritin levels may shed more light on prognosis. 
The patient in this case report had a ferritin of 4500 
on initial admission, which increased to 11,000 on her 
subsequent admission indicating lack of response to 
therapy. Once anakinra was added and titrated, her 
symptoms improved and her ferritin slowly decreased 
over the course of weeks. She was safely discharged 
home with close follow up. 
KEy PoInTS
MAS is a potentially life-threatening complication of 
rheumatologic diseases, characterized by excessive 
activation of benign macrophages which lead to 
the phagocytosis of normal blood cells and injury to 
surrounding tissues. Common clinical manifestations 
include fever, pancytopenia, liver dysfunction, hepato-
splenomegaly, and hyperferritinemia. Diagnosis can be 
difficult as the signs and symptoms of MAS can mimic 
an infection or SLE flare. However, hyperferritinemia and 
elevated LDH are characteristic of MAS and may help 
distinguish and guide treatment decisions. If uncertainty 
remains, a bone marrow biopsy can usually establish 
the diagnosis. The best treatment options at this point 
include high dose steroids, immunosuppression, IVIG, 
and biologics depending on the patient’s laboratory and 
clinical response.
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